Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines by Aileen Ebenig, Mona V. Lange, Michael D. Mühlebach

Get full text

A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9 by Cindy Hörner, Anna H. Fiedler, Bianca S. Bodmer, Lisa Walz, Vivian A. Scheuplein, Stefan Hutzler, Mikhail N. Matrosovich, Veronika von Messling, Michael D. Mühlebach

Get full text

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective by Dina Kleinlützum, Dina Kleinlützum, Dina Kleinlützum, Julia D. S. Hanauer, Alexander Muik, Kay-Martin Hanschmann, Sarah-Katharina Kays, Camilo Ayala-Breton, Kah-Whye Peng, Michael D. Mühlebach, Tobias Abel, Christian J. Buchholz, Christian J. Buchholz

Get full text

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors by Jan RH Hanauer, Lisa Gottschlich, Dennis Riehl, Tillmann Rusch, Vivian Koch, Katrin Friedrich, Stefan Hutzler, Steffen Prüfer, Thorsten Friedel, Kay-Martin Hanschmann, Robert C Münch, Christian Jost, Andreas Plückthun, Klaus Cichutek, Christian J Buchholz, Michael D Mühlebach

Get full text